医药生物行业点评报告:siRNA药物快速发展,国内药企出海潜力大

开源证券
22 Jul

(以下内容从开源证券《医药生物行业点评报告:siRNA药物快速发展,国内药企出海潜力大》研报附件原文摘录)诺华2025H1业绩公布,长效siRNA用药Leqvio销售高增2025年7月17日,诺华公布2025H1业绩,上半年净销售额为272.87亿美元(同比+13%);净利润为76.33亿美元(同比+31%)。单产品来看,长效siRNAPCSK9产品Leqvio在2021-2024年保持高速增长,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10